MaxCyte 관리

관리 기준 확인 2/4

MaxCyte CEO는 Maher Masoud, Jan2024 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 $ 890.37K, 50.5% 로 구성됩니다. 50.5% 급여 및 49.5% 보너스(회사 주식 및 옵션 포함). 는 € 326.03K 가치에 해당하는 회사 주식의 0.095% 직접 소유합니다. 326.03K. 경영진과 이사회의 평균 재임 기간은 각각 1.5 년과 3.4 년입니다.

주요 정보

Maher Masoud

최고 경영자

US$890.4k

총 보상

CEO 급여 비율	50.5%
CEO 임기	less than a year
CEO 소유권	0.09%
경영진 평균 재임 기간	1.5yrs
이사회 평균 재임 기간	3.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Maher Masoud 의 보수는 MaxCyte 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$36m
Jun 30 2024	n/a	n/a	-US$35m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$890k	US$450k	-US$38m
Sep 30 2023	n/a	n/a	-US$37m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$791k	US$413k	-US$24m

보상 대 시장: Maher 의 총 보상 ($USD 890.37K )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 995.28K ).

보상과 수익: 회사가 수익성이 없는 동안 Maher 의 보상이 증가했습니다.

CEO

Maher Masoud (49 yo)

less than a year

테뉴어

US$890,365

보상

Mr. Maher Masoud is President, CEO & Executive Director of MaxCyte, Inc. since January 1, 2024 and served as its Head of Global Business Development and Legal Officer since November 2023 and had been its S...

리더십 팀

이름	위치	테뉴어	보상	소유권
Maher Masoud	President	less than a year	US$890.37k	0.095% € 326.0k
Douglas Doerfler	Founder	26.3yrs	US$3.14m	0.32% € 1.1m
Douglas Swirsky	Chief Financial Officer	1.7yrs	US$1.29m	데이터 없음
Jay Gelfman	Senior Vice President of Operations	less than a year	데이터 없음	데이터 없음
Ronald Holtz	Executive Vice President of Administration	1.7yrs	US$948.33k	데이터 없음
David Sandoval	Senior Vice President	less than a year	데이터 없음	데이터 없음
Thomas Ross	Executive Vice President of Global Sales	10.2yrs	데이터 없음	0.024% € 81.5k
Jack Horgan	Vice President of Corporate Development	1.1yrs	데이터 없음	데이터 없음
Jill Mayer	Senior Vice President of Human Resources	less than a year	데이터 없음	데이터 없음
J. Thompson	Consultant	3.1yrs	US$264.50k	데이터 없음
James Brady	Senior VP of Technical Applications & Customer Support	3.3yrs	데이터 없음	데이터 없음
Ali Soleymannezhad	Chief Commercial Officer	1.3yrs	데이터 없음	데이터 없음

1.5yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 관리: MYE0 의 관리팀은 경험 (평균 재직 기간 1.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Maher Masoud	President	less than a year	US$890.37k	0.095% € 326.0k
William Brooke	Independent Non-Executive Director	20.7yrs	US$177.24k	0.048% € 164.0k
Arthur Mandell	Independent Non-Executive Director	18.5yrs	US$170.49k	0.36% € 1.2m
Patrick Balthrop	Independent Non-Executive Director	2yrs	US$155.49k	0% € 0
Richard Douglas	Independent Non-Executive Chairman of the Board	6.8yrs	US$190.49k	0.095% € 326.0k
Stanley Erck	Independent Non-Executive Director	19.7yrs	US$162.24k	0.23% € 807.7k
John Johnston	Independent Non-Executive Director	8.8yrs	US$160.49k	0.11% € 393.2k
Yasir Al-Wakeel	Independent Non-Executive Director	3.4yrs	US$238.53k	0% € 0
Rekha Hemrajani	Independent Non-Executive Director	3.4yrs	US$243.03k	0% € 0
Marcela Maus	Member of Scientific Advisory Board	1.7yrs	데이터 없음	데이터 없음
Cenk Sumen	Member of Scientific Advisory Board	less than a year	US$897.25k	0% € 0
Oliver Rando	Member of Scientific Advisory Board	1.7yrs	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: MYE0 의 이사회는 경험(평균 재직 기간 3.4 년)으로 간주됩니다.

MaxCyte 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

MaxCyte, Inc. Announces Appointment of Cynthia Collins as Non-Executive Director

MaxCyte, Inc. Appoints Ali Soleymannezhad as Chief Commercial Officer

President recently bought €455k worth of stock

MaxCyte, Inc., Annual General Meeting, Jun 11, 2024

MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer

Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

Recent updates

Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.11 loss in 3Q 2023)

MaxCyte, Inc. Updates Revenue Guidance for the Full Year 2024

MaxCyte, Inc. Announces Appointment of Cynthia Collins as Non-Executive Director

MaxCyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024

MaxCyte, Inc. Appoints Ali Soleymannezhad as Chief Commercial Officer

Second quarter 2024 earnings released: US$0.09 loss per share (vs US$0.10 loss in 2Q 2023)

MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024

New major risk - Share price stability

MaxCyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth Index

President recently bought €455k worth of stock

New major risk - Revenue and earnings growth

Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.092 loss per share (vs US$0.11 loss in 1Q 2023)

MaxCyte, Inc., Annual General Meeting, Jun 11, 2024

MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024

MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$0.37 loss per share (vs US$0.23 loss in FY 2022)

MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024

MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024

MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer

MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

MaxCyte, Inc. Provides Revenue Guidance Update for 2023

New major risk - Revenue and earnings growth

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.063 loss in 3Q 2022)

MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

New major risk - Revenue and earnings growth

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.081 loss in 2Q 2022)

MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023

High number of new directors

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

High number of new directors

Key Executive recently bought €319k worth of stock

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)

MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023

MaxCyte, Inc. Appoints Patrick J. Balthrop, Sr. as Class II Director and Member of Nominating Committee and Corporate Governance Committee

MaxCyte, Inc. Provides Revenue Guidance for 2022

Third quarter 2022 earnings released: US$0.063 loss per share (vs US$0.032 loss in 3Q 2021)

MaxCyte, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Maxcyte, Inc. Revenue Guidance for 2022

Second quarter 2022 earnings released: US$0.081 loss per share (vs US$0.052 loss in 2Q 2021)

MaxCyte, Inc. to Report Q2, 2022 Results on Aug 10, 2022

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2000 Growth Index

MaxCyte, Inc., Annual General Meeting, Jun 29, 2022

First quarter 2022 earnings released: US$0.04 loss per share (vs US$0.088 loss in 1Q 2021)

MaxCyte, Inc. Provides Revenue Guidance for the Full Year 2022

MaxCyte, Inc. to Report Q1, 2022 Results on May 09, 2022

Maxcyte, Inc. Announces CFO Changes, Effective as of April 15, 2022

MaxCyte, Inc. to Report Q4, 2021 Results on Mar 22, 2022

Maxcyte, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Independent Chairman of the Board recently bought €197k worth of stock

Founder recently sold €1.1m worth of stock

Third quarter 2021 earnings released: US$0.032 loss per share (vs US$0.037 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.052 loss per share (vs US$0.046 loss in 2Q 2020)

MaxCyte, Inc. Provides Preliminary Revenue Guidance for the Year 2021

High number of new directors

Forecast breakeven pushed back to 2023

Full year 2020 earnings released: US$0.17 loss per share (vs US$0.23 loss in FY 2019)

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령